Recent advances in systemic therapy: advances in neoadjuvant (primary) systemic therapy with cytotoxic agents.
Neoadjuvant therapy, also known as primary, induction, or preoperative therapy, is defined as the first systemic treatment a patient receives after cancer is diagnosed and indicates that subsequent therapies are intended. It was first used in the early 1970s for the treatment of inoperable locally advanced or inflammatory breast cancer. Based on a large body of clinical evidence and on the fact that primary breast cancer is today considered a systemic disease with a locoregional component, primary systemic therapy is now increasingly considered for women with operable disease for reducing mortality with lower toxicity, improving surgical options, and acquiring early information on response and biology of the disease.
Untch
Michael
M
HELIOS Klinikum Berlin-Buch, Akademisches LK der Universität Charité, Berlin, Germany. michael.untch@helios-kliniken.de
von Minckwitz
Gunter
G